Tandem Diabetes Care (TNDM) EPS (Basic) Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -6.15% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 7.72% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -1.10% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 62.43% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 10.44% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 58.74% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 26.49% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 5.98% |
| 10 | Tandem Diabetes Care | 1.31 Bn | 739.55 Mn | 136.79 Mn | 46.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 46.14% |
| Dec 31, 2025 | 65.80% |
| Sep 30, 2025 | 25.84% |
| Jun 30, 2025 | -50.24% |
| Mar 31, 2025 | -104.60% |
| Dec 31, 2024 | -61.11% |
| Sep 30, 2024 | -80.58% |
| Jun 30, 2024 | -114.24% |
| Mar 31, 2024 | -101.04% |
| Dec 31, 2023 | -54.72% |
| Sep 30, 2023 | -50.37% |
| Jun 30, 2023 | -6.92% |
| Mar 31, 2023 | -97.30% |
| Dec 31, 2022 | -102.06% |
| Sep 30, 2022 | -147.71% |
| Jun 30, 2022 | -97.18% |
| Mar 31, 2022 | 16.84% |
| Dec 31, 2021 | 41.50% |
| Sep 30, 2021 | 28.97% |
| Jun 30, 2021 | 27.06% |
| Mar 31, 2021 | 64.71% |
| Dec 31, 2020 | 30.44% |
| Sep 30, 2020 | 63.52% |
| Jun 30, 2020 | 53.09% |
| Mar 31, 2020 | 67.76% |
| Dec 31, 2019 | 26.17% |
| Sep 30, 2019 | 82.73% |
| Jun 30, 2019 | 82.90% |
| Mar 31, 2019 | 61.11% |
| Dec 31, 2018 | 29.07% |
| Sep 30, 2018 | 1.56% |
| Jun 30, 2018 | -21.64% |
| Mar 31, 2018 | -29.92% |
| Dec 31, 2017 | -16.40% |
| Sep 30, 2017 | -53.76% |
| Jun 30, 2017 | -73.83% |
| Mar 31, 2017 | -98.07% |
| Dec 31, 2016 | -30.90% |
| Sep 30, 2016 | 45.81% |
| Jun 30, 2016 | 56.42% |
| Mar 31, 2016 | 49.81% |